請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55633
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余佳慧 | |
dc.contributor.author | Kaun-Yang Hung | en |
dc.contributor.author | 洪冠陽 | zh_TW |
dc.date.accessioned | 2021-06-16T04:13:55Z | - |
dc.date.available | 2016-10-09 | |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-20 | |
dc.identifier.citation | 1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:Ii43-7.
2. Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012;46:356-66. 3. Dorn SD, Morris CB, Hu Y, et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol 2009;43:214-20. 4. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73. 5. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31. 6. Chitkara DK, van Tilburg MA, Blois-Martin N, et al. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 2008;103:765-74; quiz 775. 7. Bradford K, Shih W, Videlock EJ, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012;10:385-90.e1-3. 8. Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004;53:1102-8. 9. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7. 10. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009;15:3591-6. 11. Drossman DA. Mind over matter in the postinfective irritable bowel. Gut 1999;44:306-7. 12. Gwee KA, Read NW, Graham JC, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. The Lancet 1996;347:150-153. 13. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42 Suppl 17:41-7. 14. D'Anchino M, Orlando D, De Feudis L. Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome. J Infect 2002;45:169-72. 15. Nygard K, Schimmer B, Sobstad O, et al. A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Public Health 2006;6:141. 16. Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect 2007;55:524-30. 17. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-50. 18. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97-105. 19. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. 20. Martinez C, Gonzalez-Castro A, Vicario M, et al. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 2012;6:305-15. 21. Ghoshal UC, Shukla R, Ghoshal U, et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085. 22. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009;403:47-55. 23. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57. 24. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-34. 25. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34. 26. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66. 27. Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid (Online) 2012;2012. 28. Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med (Berl) 2006;84:544-50. 29. Rehfeld JF, Bungaard JR, Friis-Hansen L, et al. On the tissue-specific processing of procholecystokinin in the brain and gut--a short review. J Physiol Pharmacol 2003;54 Suppl 4:73-9. 30. Liddle RA. Cholecystokinin cells. Annu Rev Physiol 1997;59:221-42. 31. Varga G, Balint A, Burghardt B, et al. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004;141:1275-84. 32. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805-47. 33. Friedrich AE, Gebhart GF. Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla. Pain 2003;104:93-101. 34. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004;92:1982-9. 35. Bohn L, Storsrud S, Tornblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108:634-41. 36. Van Der Veek PP, Biemond I, Masclee AA. Proximal and distal gut hormone secretion in irritable bowel syndrome. Scand J Gastroenterol 2006;41:170-7. 37. Zhang H, Yan Y, Shi R, et al. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008;78:72-6. 38. Dizdar V, Spiller R, Singh G, et al. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010;31:883-91. 39. van der Schaar PJ, van Hoboken E, Ludidi S, et al. Effect of cholecystokinin on rectal motor and sensory function in patients with irritable bowel syndrome and healthy controls. Colorectal Dis 2013;15:e29-34. 40. Sabate JM, Gorbatchef C, Flourie B, et al. Cholecystokinin octapeptide increases rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002;14:689-95. 41. Chey WY, Chang T. Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology 2001;1:320-35. 42. Coffin B, Fossati S, Flourie B, et al. Regional effects of cholecystokinin octapeptide on colonic phasic and tonic motility in healthy humans. Am J Physiol 1999;276:G767-72. 43. Enck P, Kaiser C, Felber M, et al. Circadian variation of rectal sensitivity and gastrointestinal peptides in healthy volunteers. Neurogastroenterol Motil 2009;21:52-8. 44. Harvey RF, Read AE. Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable-bowel syndrome. Lancet 1973;1:1-3. 45. Renny A, Snape WJ, Jr., Sun EA, et al. Role of cholecystokinin in the gastrocolonic response to a fat meal. Gastroenterology 1983;85:17-21. 46. Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 2011;141:2098-2108.e5. 47. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923-9. 48. Hong S, Zheng G, Wu X, et al. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 2011;140:627-637.e4. 49. Stengel A, Tache Y. Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) 2010;235:1168-78. 50. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53:958-64. 51. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-8. 52. Santos J, Saunders PR, Hanssen NP, et al. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol 1999;277:G391-9. 53. Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004;16 Suppl 1:137-42. 54. Larauche M, Bradesi S, Million M, et al. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 2008;294:G1033-40. 55. Barreau F, Cartier C, Leveque M, et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007;580:347-56. 56. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. 57. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9. 58. Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta 2012;1822:85-92. 59. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. 60. van Diest SA, Stanisor OI, Boeckxstaens GE, et al. Relevance of mast cell-nerve interactions in intestinal nociception. Biochim Biophys Acta 2012;1822:74-84. 61. Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem 2005;280:31936-48. 62. Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 2010;189:111-26. 63. Gershon MD. The enteric nervous system: a second brain. Hosp Pract (1995) 1999;34:31-2, 35-8, 41-2 passim. 64. Bienenstock J, Collins S. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: psycho-neuroimmunology and the intestinal microbiota: clinical observations and basic mechanisms. Clin Exp Immunol 2010;160:85-91. 65. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011;62:381-96. 66. Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009;141:191-209. 67. Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 2009:31-74. 68. Kiyatkin ME, Feng B, Schwartz ES, et al. Combined genetic and pharmacological inhibition of TRPV1 and P2X3 attenuates colorectal hypersensitivity and afferent sensitization. Am J Physiol Gastrointest Liver Physiol 2013;305:G638-48. 69. Okun A, Liu P, Davis P, et al. Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain 2012;153:924-33. 70. Parekh R, Ascoli GA. Quantitative Investigations of Axonal and Dendritic Arbors: Development, Structure, Function, and Pathology. Neuroscientist 2014. 71. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47. 72. Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591-9. 73. Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106:1290-8. 74. Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012;61:685-94. 75. Barreau F, Cartier C, Ferrier L, et al. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 2004;127:524-34. 76. Torrents D, Torres R, De Mora F, et al. Antinerve growth factor treatment prevents intestinal dysmotility in Trichinella spiralis-infected rats. J Pharmacol Exp Ther 2002;302:659-65. 77. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006;361:1545-64. 78. Dhobale M. Neurotrophins: Role in adverse pregnancy outcome. Int J Dev Neurosci 2014;37c:8-14. 79. Benito-Gutierrez E, Garcia-Fernandez J, Comella JX. Origin and evolution of the Trk family of neurotrophic receptors. Molecular and Cellular Neuroscience 2006;31:179-192. 80. Kuroda T, Yokoyama J, Endo M, et al. Intestinal localization of nerve growth factor in normal rats, mice, and megacolonic mice. Journal of Pediatric Surgery 1993;28:575. 81. Tirassa P, Costa N. CCK-8 induces NGF and BDNF synthesis and modulates TrkA and TrkB expression in the rat hippocampus and septum: Effects on kindling development. Neurochem Int 2007;50:130-8. 82. Tirassa P, Stenfors C, Lundeberg T, et al. Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors. Br J Pharmacol 1998;123:1230-6. 83. Brown A, Ricci MJ, Weaver LC. NGF message and protein distribution in the injured rat spinal cord. Exp Neurol 2004;188:115-27. 84. Mimura J, Kosaka K, Maruyama A, et al. Nrf2 regulates NGF mRNA induction by carnosic acid in T98G glioblastoma cells and normal human astrocytes. J Biochem 2011;150:209-17. 85. Skaper SD, Pollock M, Facci L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res Mol Brain Res 2001;97:177-85. 86. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A 1994;91:3739-43. 87. Kuroda T, Ueda M, Nakano M, et al. Altered production of nerve growth factor in aganglionic intestines. J Pediatr Surg 1994;29:288-92; discussion 292-3. 88. Willot S, Gauthier C, Patey N, et al. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:734-9, e347. 89. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-2. 90. Fulmer CG, VonDran MW, Stillman AA, et al. Astrocyte-derived BDNF supports myelin protein synthesis after cuprizone-induced demyelination. J Neurosci 2014;34:8186-96. 91. Zhang R, Peng Z, Wang H, et al. Gastrodin ameliorates depressive-like behaviors and up-regulates the expression of BDNF in the hippocampus and hippocampal-derived astrocyte of rats. Neurochem Res 2014;39:172-9. 92. Bercik P, Park AJ, Sinclair D, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 2011;23:1132-9. 93. Yu SJ, Grider JR, Gulick MA, et al. Up-regulation of brain-derived neurotrophic factor is regulated by extracellular signal-regulated protein kinase 5 and by nerve growth factor retrograde signaling in colonic afferent neurons in colitis. Exp Neurol 2012;238:209-17. 94. Winston JH, Sarna SK. Developmental origins of functional dyspepsia-like gastric hypersensitivity in rats. Gastroenterology 2013;144:570-579.e3. 95. Boesmans W, Gomes P, Janssens J, et al. Brain-derived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system. Gut 2008;57:314-22. 96. Lucini C, Maruccio L, de Girolamo P, et al. Localisation of neurotrophin - containing cells in higher vertebrate intestine. Anat Embryol (Berl) 2002;205:135-40. 97. Zhu ZW, Friess H, Wang L, et al. Brain-derived neurotrophic factor (BDNF) is upregulated and associated with pain in chronic pancreatitis. Dig Dis Sci 2001;46:1633-9. 98. Yang J, Yu Y, Yu H, et al. The role of brain-derived neurotrophic factor in experimental inflammation of mouse gut. Eur J Pain 2010;14:574-9. 99. Kaplan DR, Matsumoto K, Lucarelli E, et al. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron 1993;11:321-31. 100. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741-7. 101. Encinas M, Iglesias M, Llecha N, et al. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem 1999;73:1409-21. 102. Pahlman S, Hoehner JC, Nanberg E, et al. Differentiation and survival influences of growth factors in human neuroblastoma. European Journal of Cancer 1995;31:453-458. 103. Simpson PB, Bacha JI, Palfreyman EL, et al. Retinoic acid evoked-differentiation of neuroblastoma cells predominates over growth factor stimulation: an automated image capture and quantitation approach to neuritogenesis. Anal Biochem 2001;298:163-9. 104. Oe T, Sasayama T, Nagashima T, et al. Differences in gene expression profile among SH-SY5Y neuroblastoma subclones with different neurite outgrowth responses to nerve growth factor. J Neurochem 2005;94:1264-76. 105. Sikandar S, Dickenson AH. Pregabalin modulation of spinal and brainstem visceral nociceptive processing. Pain 2011;152:2312-22. 106. Palecek J, Willis WD. The dorsal column pathway facilitates visceromotor responses to colorectal distention after colon inflammation in rats. Pain 2003;104:501-7. 107. Manni L, Lundeberg T, Tirassa P, et al. Cholecystokinin-8 enhances nerve growth factor synthesis and promotes recovery of capsaicin-induced sensory deficit. Br J Pharmacol 2000;129:744-50. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55633 | - |
dc.description.abstract | 背景:IBS是一種常見的功能性腸道異常疾病,症狀包括長期反覆性腹痛、腹脹並伴隨排便習慣改變,但卻無法檢測出病原體或腸道結構型態的改變。目前對腸躁症腹痛敏感的病理機制尚不清楚。本研究目的是利用梨形蟲感染後結合避水壓力雙重因子刺激建立的IBS小鼠模式,探討其腸道組織上的分子變化,並將腸清液與人類神經母細胞培養,觀察神經纖維的生長變化,以瞭解神經細胞型態改變與內臟痛覺高敏感化的相關性。方法:小鼠在第0天時給予灌食梨形蟲(Giardia lamblia)或磷酸鹽緩衝液(PBS),在後排除期的第35-44天進行10天的避水壓力(water avoidance stress,WAS)或無處理(non-handle,NH),共分作四大組(PBS-NH, PBS-WAS, Giardia-NH, Giardia-WAS)。將小鼠於第44天時利用結直腸撐張刺激進行內臟動器反應分析,而後犧牲並收集腸段製備成腸組織上清液。利用人類SH-SY5Y神經母細胞株,加入視黃酸促使分化後,再給予腸組織上清液培養,觀察神經纖維生長變化。結果: 神經母細胞經視黃酸和腦源性生長因子作用後,神經纖維生長為4倍,當作一個正對照組。接著測試四大組小鼠腸組織上清液對神經纖維生長的影響,結果顯示PBS-WAS, Giardia-NH, Giardia-WAS小鼠腸清液相比於PBS-NH組,會分別促使神經細胞纖維長度上升約2,2.5和3倍。透過西方轉漬法分析小鼠腸道組織中的神經營養因子表現量發現,在小腸組織方面,Giardia-WAS 組小鼠的NGF總量有明顯上升;在大腸組織方面,BDNF表現量則有上升的趨勢。在神經細胞實驗中,預先給予中和性anti-NGF或anti-BDNF均能顯著降低Giardia-WAS組小鼠腸清液培養後神經纖維的長度;或預先將CCK receptor antagonists (AIH或BIH)加入神經細胞上,亦能抑制神經細胞纖維的延長。此外,若將腹腔注射AIH或BIH小鼠之腸清液與神經細胞培養則發現,BIH注射小鼠之腸清液能抑制神經細胞纖維的延長,AIH則無法抑制。最後透過西方轉漬法分析發現SH-SY5Y神經細胞會常態性的表現CCK-AR, CCK-BR, BDNF,但不表現CCK和NGF;而在給予小鼠腸清液培養後,NGF總量會增加。結論:本篇研究證明了內臟痛覺敏感化的小鼠腸道中含有CCK、NGF與BDNF的存在,而這些腸源性因子會影響神經細胞纖維的延長而參與導致痛覺異常。 | zh_TW |
dc.description.abstract | Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits, without macroscopic abnormality or presence of pathogen. The mechanism of visceral hypersensitivity in IBS is still unclear. The aim is to investigate the molecular changes in intestinal tissues of a mouse model of IBS with visceral hypersensitivity caused by dual stressors of post-infection and psychological stress, and to evaluate whether gut-derived factors may cause neurite outgrowth by using a human neuroblastoma SH-SY5Y cell line. Method: Mice were inoculated with Giardia lamblia or phosphate-buffered saline (PBS) via orogastric gavage on day 0, and subjected to 10-day water avoidance stress (WAS) or non-handle (NH) from day 35-44 during post-clearance phase. Mice were divided to four groups: PBS-NH, PBS-WAS, Giardia-NH, Giardia-WAS. Visceromotor response to colorectal distension was analyzed in mice on day 44, and then intestinal segments were collected for preparation of gut tissue supernatant. SH-SY5Y cells were treated with retinoic acid to induce the cell differentiation and then cultured with gut tissue supernatant for measurement of nerve fiber length. Result: SH-SY5Y cells treated with retinoic acid and brain-derived neurotrophic factor showed 4-times longer nerve fiber length, which served as a positive control. As for the effect of gut-derived factors on neurite outgrowth, incubation of gut supernatant obtained from PBS-WAS, Giardia-NH, and Giardia-WAS mice caused 1.5-, 2-, and 2.5- times increases in nerve fiber length compared to that from PBS-NH mice, respectively. Western blotting results showed increased expression of NGF in small intestine, and increased expression of BDNF in large intestine. Moreover, addition of neutralizing anti-NGF or anti-BDNF reduced the nerve fiber length incubated with G-WAS gut supernatant; pretreatment with CCK receptor antagonist (AIH or BIH) also inhibited neurite outgrowth. In addition, when culturing SH-SY5Y cells with gut supernatant obtained from mice intraperitoneally injected with AIH or BIH, the BIH-injected gut supernatant decreased the nerve fiber length while the AIH-injected gut supernatant did not. Finally, Western blotting showed that SH-SY5Y cells constitutively expressed CCK-AR, CCK-BR, and BDNF, but not CCK or NGF; increased levels of NGF was seen after culturing with gut supernatant. Conclusion: Presence of CCK, NGF, and BDNF was found in the intestine of mice with visceral hypersensitivity, and these gut-derived factors affect the outgrowth of neurites and may lead to abnormal pain sensation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T04:13:55Z (GMT). No. of bitstreams: 1 ntu-103-R01441018-1.pdf: 2277865 bytes, checksum: 73e2e72468af313019c1178cba5836c2 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 II 英文摘要 III 一、前言 12 1.腸躁症(irritable bowel syndrome, IBS) 1 1.1流行病學研究 1 1.2.危險因子(risk factors)探討 1 1.2.1精神壓力 1 1.2.2腸胃道感染和後感染腸躁症(postinfectious irritable bowel syndrome,PI-IBS) 2 2.IBS臨床研究與可能參與之分子機制探討 3 2.1 血清素(serotonin) 3 2.2膽囊收縮素-胰泌素(Cholecystokinin-Pancreozymin,CCK-PZ) 4 2.3下視丘-腦下垂體-腎上腺皮質軸與腎上腺皮質酮(hypothalamic-pituitary-adrenal axis and corticosterone) 5 2.4 肥大細胞 6 3.腦腸軸(brain-gut axis, BGA)異常和內臟高敏感性 (visceral hypersensitivity) 6 4.痛覺敏感化與神經細胞功能型態之間的關聯性 7 4.1 IBS病人之神經功能改變 8 4.2 IBS病人之神經型態改變 8 4.3神經營養因子(Neurotrophins) 8 4.3.1神經生長因子(Nerve growth factor,NGF) 9 4.3.2腦源性神經營養因子(Brain-derived neurotrophic factor,BDNF) 9 5. 人類神經母細胞瘤SH-SY5Y細胞株作神經分化和纖維生長的模式 10 6. 研究目的 11 二、材料與方法 12 1.實驗動物 12 2.動物模式 12 2.1寄生蟲感染模式 12 2.2 動物精神壓力模式 12 2.3 實驗方法和時程 13 4.腸清液(gut supernatant)無菌製備 14 5.動物內臟動器反應(visceromotor response, VMR)分析 15 6.細胞試驗 15 6.1 使用細胞株 15 6.2神經纖維生長(neurite outgrowth)實驗 16 6.3細胞影像的擷取與神經細胞纖維長度測量 18 7. 細胞實驗使用之中和性抗體和拮抗劑 18 7.1 Neutralizing anti-NGF 18 7.2 Neutralizing anti-BDNF 18 7.3 CCK receptor inhibitors 19 8. 西方轉漬法(Western blotting) 19 8.1. 細胞蛋白質萃取 19 8.2. 蛋白質定量 19 8.3. 蛋白質電泳 20 8.4. 蛋白質分析 20 四、實驗結果 23 1. SH-SY5Y神經母細胞經Retinoic Acid和Brain-derived nerve growth factor刺激後之神經纖維長度 23 2.探討小鼠腸清液對SH-SY5Y神經細胞纖維長度的影響 23 2.1小鼠空腸上清液引起SH-SY5Y神經細胞纖維長度的變化 23 2.2小鼠結腸上清液引起SH-SY5Y神經細胞纖維長度的變化 24 3.探討IBS動物模式中腸道組織NGF與BDNF的含量 25 4. 探討中和性抗體處理SH-SY5Y 細胞對神經纖維長度的影響 25 5. 探討拮抗劑處理SH-SY5Y 細胞對神經纖維長度的影響 26 6. 探討腹腔注射拮抗劑小鼠之腸清液是否影響神經細胞纖維生長 27 7. 探討腸清液培養後之SH-SY5Y神經細胞上CCK、CCK-AR、CCK-BR、NGF、BDNF的表現量 28 五、討論 29 參考文獻 42 | |
dc.language.iso | zh-TW | |
dc.title | 後感染排除小鼠腸道上清液刺激人類神經母細胞瘤SH-SY5Y之神經纖維生長 | zh_TW |
dc.title | Stimulation of neurite outgrowth in human neuroblastoma SH-SY5Y cells by post-infectious mouse intestinal supernatant | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 游瑋絢,孫錦虹,忻凌偉 | |
dc.subject.keyword | 腸躁症,梨形蟲,內臟高敏感性,神經生長, | zh_TW |
dc.subject.keyword | irritable bowel syndrome(IBS),Giardia lamblia,visceral hypersensitivity,nerve outgrowth, | en |
dc.relation.page | 49 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 2.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。